Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNA-Typing and RBC-MPs for Blood Doping Detection
NCT03548766Phase 3Unknown
- Sponsor
- Hamad Medical Corporation
- Start
- Sep 2018
- Primary completion
- Dec 2021
- Countries
- 1
01
Overview
Phase 3, open-label trial (2 arms), sponsored by Hamad Medical Corporation. Primary endpoints: Donor DNA (# of loci with triplets or quadruplets) at 12 months and Cellular Microparticles at 12 months. Status: unknown.
Beyond the preview
Go deeper on NCT03548766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03548766.